Calidi Biotherapeutics Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

CLDI$0.73+4.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

	Three Months Ended March 31,
	2024	2023
(Unaudited)
OPERATING EXPENSES
Research and development	$(2,743)	$(2,622)
General and administrative	(4,009)	(2,792)
Total operating expense	(6,752)	(5,414)
Loss from operations	(6,752)	(5,414)
OTHER INCOME (EXPENSES), NET
Interest expense	(98)	(67)
Interest expense – related party	(155)	(150)
Change in fair value of debt, other liabilities, and derivatives	(198)	(1,026)
Change in fair value of debt, other liabilities, and derivatives – related party	(1)	(487)
Grant income	—	691
Other expense, net	(17)	(5)
Total other expenses, net	(469)	(1,044)
LOSS BEFORE INCOME TAXES	(7,221)	(6,458)
Income tax provision	(4)	(4)
NET LOSS	$(7,225)	$(6,462)
Net loss per share; basic and diluted	$(0.20)	$(0.75)
Weighted average common shares outstanding; basic and diluted	35,552	8,655

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

	Three Months Ended March 31,
	2024	2023
(Unaudited)
NET LOSS	$(7,225)	$(6,462)
Other comprehensive income, net of tax:
Foreign currency translation adjustment	58	2
COMPREHENSIVE LOSS	$(7,167)	$(6,460)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.